HMLEE personal page - To The Moon

HMLEE

No personal profile

3Follow

2Followers

0Topic

0Badge

2021-06-29

Good one

Sorry, the original content has been removed

2021-06-30

.

China Cancer Drugmaker Surges 28% in Hong Kong Trading Debut

2021-06-29

$ISDN HOLDINGS LIMITED(I07.SI)$ Huat ar

2021-06-29

Wow

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3583141439554126,"uuid":"3583141439554126","gmtCreate":1620048603309,"gmtModify":1620048603309,"name":"HMLEE","pinyin":"hmlee","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":3,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":153847416,"gmtCreate":1625019220735,"gmtModify":1703850246815,"author":{"id":"3583141439554126","authorId":"3583141439554126","authorIdStr":"3583141439554126","name":"HMLEE","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583141439554126"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153847416","repostId":"1124855646","repostType":4,"isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159846478,"gmtCreate":1624958215794,"gmtModify":1703848825754,"author":{"id":"3583141439554126","authorId":"3583141439554126","authorIdStr":"3583141439554126","name":"HMLEE","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583141439554126"},"themes":[],"htmlText":"Good one","listText":"Good one","text":"Good one","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/159846478","repostId":"2147832042","repostType":4,"repost":{"id":"2147832042","pubTimestamp":1624958100,"share":"https://ttm.financial/m/news/2147832042?lang=&edition=fundamental","pubTime":"2021-06-29 17:15","market":"us","language":"en","title":"JPMorgan: These 3 Stocks Could Spike at Least 70% From Current Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2147832042","media":"TipRanks","summary":"Let’s step back and take a look at the big picture, while keeping stocks in focus. Both the S&P 500 ","content":"<div>\n<p>Let’s step back and take a look at the big picture, while keeping stocks in focus. Both the S&P 500 and the Nasdaq hit a series of record highs -- mainly due to increasing investor confidence that the...</p>\n\n<a href=\"https://www.tipranks.com/news/article/jpmorgan-these-3-stocks-could-spike-at-least-70/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan: These 3 Stocks Could Spike at Least 70% From Current Levels</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan: These 3 Stocks Could Spike at Least 70% From Current Levels\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/jpmorgan-these-3-stocks-could-spike-at-least-70/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Let’s step back and take a look at the big picture, while keeping stocks in focus. Both the S&P 500 and the Nasdaq hit a series of record highs -- mainly due to increasing investor confidence that the...</p>\n\n<a href=\"https://www.tipranks.com/news/article/jpmorgan-these-3-stocks-could-spike-at-least-70/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATUS":"Altice USA Inc.","DAWN":"Day One Biopharmaceuticals Inc.","SMWB":"Similarweb Ltd."},"source_url":"https://www.tipranks.com/news/article/jpmorgan-these-3-stocks-could-spike-at-least-70/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147832042","content_text":"Let’s step back and take a look at the big picture, while keeping stocks in focus. Both the S&P 500 and the Nasdaq hit a series of record highs -- mainly due to increasing investor confidence that the current inflationary environment will be a transitory event rather than a sustained trend. Clearly, investors are not shy about stocks, even though the Commerce Department’s inflation indicator for May hit 3.4%, it’s fastest rate of increase since the 90s.\nGiven this alarming disconnect, it has become more challenging to predict where the market might be heading. Economic and political forces are pulling in different directions, and the greatest certainty for now is uncertainty.\nThat’s not to say there aren’t any compelling plays out there. Against this backdrop, the pros from investment firm JPMorgan argue that a select few stocks stand to gain, pointing to three in particular that represent exciting opportunities. Not to mention potential upside gains starting at 70% are on the table.\nWe ran them through TipRanks database to see what other Wall Street analysts have to say about them. Let's take a closer look.\nDay One Biopharmaceuticals (DAWN)\nWe’ll start with Day One Biopharma, a clinical stage medical company focused on developing new treatments for genetically defined cancers. Day One takes an ‘all-ages’ approach to its new drug development, working on medications that will benefit the largest cohort of patients, from youth to adults.\nDay One’s leading drug candidate is DAY101, an orally dosed, selective type II pan-RAF kinase inhibitor, under evaluation in a pivotal Phase 2 trial (the FIREFLY-1 trial) that has enrolled pediatric, adolescent, and young adult patients. All the patients in the study suffer from recurrent or progressive low-grade glioma (pLGG).\nDAY101 has received two important designations from the FDA, the breakthrough drug designation and the orphan drug designation, and the company has additional clinical trials planned. The Phase 1 FIREFLY-2 trial, will test the drug against frontline pLGG, and there is a Phase 1 monotherapy trial for adults with RAF-altered solid tumors. Day One also has plans to initiate a Phase 1/2 trial, testing DAY101 in combination with primasertip in patients over age 12 and diagnosed with recurrent, progressive, or refractory solid tumors with MAPK pathway aberrations.\nThe company held its IPO in late May, putting 10 million shares on the market at $16 per share. The event raised gross proceeds of $160 million. DAWN is now listed on the NASDAQ index, and has a market cap of $1.24 billion.\nJPMorgan analyst Anupam Rama likes the fundamental of this newly biotech stock. The analyst rates DAWN an Overweight (i.e. Buy) along with a $38 price target. Shares could appreciate by 89%, should the analyst's thesis play out in the coming months.\n“Our Overweight thesis is driven by lead asset DAY101 (type 2 pan-RAF kinase inhibitor) which is initially being developed in the lead indication of BRAF-associated relapsed pediatric low-grade glioma. Indeed, in our view, known data, which have shown early anti-tumor activity and a clean safety profile, do de-risk the ongoing phase 2 registrational FIREFLY-1 study in BRAF-associated relapsed pLGG (initial data anticipated in 1H22),” Rama opined.\nLooking ahead at future milestones, Rama noted, “Other key development milestones to monitor for DAY101 monotherapy include an adult RAF-altered solid tumor phase 2 study initiation (mid-2021) and DAY101 BRAF-associated front-line pLGG phase 3 trial initiation (1H22). The company will also start phase 1b/2 study of DAY101 + pimasertib in adult MAPK-altered solid tumors in 1Q22.”\nOverall, there is broad agreement on Wall Street with Rama’s view, as indicated by the unanimous Strong Buy consensus rating, supported by 4 recent positive reviews. Shares in DAWN are selling for $20.11 and their $37.33 average price target implies a one-year upside potential of ~86%.\n\nAltice USA, Inc. (ATUS)\nThe next JPM pick we're looking at is a telecom company, Altice USA. Altice is a cable TV provider, with 4.9 million customers across 21 states. The bulk of these customers receive service through two of Altice’s brands, Optimum and Suddenlink. Altice’s business has been solid over the long term, and the stock is up 52% in the last 12 months. The company is consistently ranked in the top 5 cable TV companies in the US market, by customer base.\nOver the past two years, since 1Q19, Altice’s revenues have been fairly steady, with the quarterly top line continually registering between $2.4 billion and $2.54 billion. In the most recent quarter reported, 1Q21, the top line was $2.48 billion. EPS told an even better story; at 58 cents per share, it was down 2 cents (or 3%) from Q4 but up strongly from the 1 cent EPS loss reported in 1Q20.\nIn a key metric, Altice reported strong cash flows in Q1. Operating cash flow grew more than 17% year-over-year, reaching $862 million. This was driven partly by earnings growth and partly by reduced capital expenditures.\nJPMorgan's Philip Cusick is impressed by Altice’s solid business foundation, noting: “We continue to like ATUS on solid fundamentals, strong capital returns, and an attractive valuation based on a 10.3% fully-taxed 2021 FCF yield and low-single digit revenue growth... Altice remains on track to achieve its 2021 residential broadband subscriber growth target of in line with or better than 2019 and 2018 growth.”\nTo this end, Cusick rates ATUS an Overweight (i.e. Buy) along with a $62 price target. This figure implies an upside of 80% for the next 12 months. \nWhat does the rest of the Street think? Looking at the consensus breakdown, opinions from other analysts are more spread out. 5 Buys, 3 Holds and 1 Sell add up to a Moderate Buy consensus. In addition, the $42.33 average price target indicates ~23% upside potential from current levels.\n\nSimilarweb (SMWB)\nWe’ll wrap up this list of JPM picks with Similarweb, a digital intelligence and web analytics company founded back in 2007 and catering to the small- to mid-sized business market. Similarweb brings its customers a ‘comprehensive and detailed view of the digital world,’ developed with proprietary analytic technology. In aggregate, Similarweb analyses over 100 million websites, 4.7 million mobile apps, and 3 million brands across 210 industries. The company gathers data on 550 million keywords every month, along with over 1 billion search terms.\nSimilarweb's revenue hit $93.5 million last year, and the company went public this past May. The IPO saw the company offer 7.5 million shares on the market, at a price of $22 per share. This was above the initial pricing range of $19 to $21. The event raised approximately $165 million in gross proceeds.\nThis newly public stock caught the attention of JPM’s 5-star analyst Sterling Auty, who sees a $34 billion addressable market in Similarweb’s niche.\n“The increasing shift towards digital routes to market including e-commerce is forcing a wide range of stakeholders to search for reliable alternative data sources to run and invest in businesses. Similarweb has established itself as a leading digital intelligence platform for data across Internet, mobile Internet, and mobile application data. That position, we believe, will lead to continued fast revenue growth and increasing operating leverage that can drive share outperformance,” Auty wrote.\nIn line with these bullish comments, Auty gives SMWB shares an Overweight (i.e. Buy) rating, and his $31 price target indicates confidence in a 70% upside for the next 12 months. \nThis new digital analytic stock has, in its short time on the public market, picked up 7 reviews from Wall Street’s analysts, with a breakdown of 5 to 2 Buy versus Hold giving the shares a Moderate Buy consensus rating. The stock is selling for $18.34 and the $27.67 average price target implies an upside of 52% for the upcoming year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":310,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159848418,"gmtCreate":1624958173034,"gmtModify":1703848824132,"author":{"id":"3583141439554126","authorId":"3583141439554126","authorIdStr":"3583141439554126","name":"HMLEE","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583141439554126"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/I07.SI\">$ISDN HOLDINGS LIMITED(I07.SI)$</a> Huat ar","listText":"<a href=\"https://laohu8.com/S/I07.SI\">$ISDN HOLDINGS LIMITED(I07.SI)$</a> Huat ar","text":"$ISDN HOLDINGS LIMITED(I07.SI)$ Huat ar","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159848418","isVote":1,"tweetType":1,"viewCount":224,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159849879,"gmtCreate":1624957978891,"gmtModify":1703848822518,"author":{"id":"3583141439554126","authorId":"3583141439554126","authorIdStr":"3583141439554126","name":"HMLEE","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583141439554126"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159849879","repostId":"2147854949","repostType":4,"repost":{"id":"2147854949","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624953169,"share":"https://ttm.financial/m/news/2147854949?lang=&edition=fundamental","pubTime":"2021-06-29 15:52","market":"sh","language":"en","title":"China stocks end lower as virus cases threaten global recovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2147854949","media":"Reuters","summary":"SHANGHAI, June 29 (Reuters) - China stocks fell on Tuesday on concerns the infectious Delta virus va","content":"<p>SHANGHAI, June 29 (Reuters) - China stocks fell on Tuesday on concerns the infectious Delta virus variant could assuage global economic recovery, while investors refrained from placing big bets ahead of U.S. jobs data, which could sway the Federal Reserve's policy outlook.</p>\n<p>The blue-chip CSI300 index closed 1.2% lower at 5,190.54, snapping a five-day winning streak, while the Shanghai Composite Index shed 0.9% to 3,573.18.</p>\n<p>Markets are on edge after the Fed shocked traders with a hawkish tilt earlier this month, while investors adopted a wait-and-watch mode ahead of the U.S. June employment report.</p>\n<p>The retreat from riskier assets followed reports of more contagious Delta COVID-19 strain spread in Asia and elsewhere, stoking fears of further lockdowns.</p>\n<p>The CSI300 financials index declined 1.3%, while the CSI300 consumer staples index dropped 1.8%.</p>\n<p>China will make its monetary policy flexible, targeted and appropriate, while keeping interbank liquidity reasonable, the central bank said on Monday, as authorities seek to consolidate a post-COVID-19 economic recovery.</p>\n<p>The country's economy has seen a rebound from the impact of the COVID-19 pandemic, with Chinese exporters racing ahead to fill global demand bolstering the vast industry sector, but the recovery in the consumer end has been weak.</p>\n<p>\"The net injection by the PBOC was to smoothen liquidity across quarters and the PBOC would probably go back to drain short-term liquidity, while large inflows via the Stock Connect are unsustainable against a backdrop of a stronger dollar,\" Yan Kaiwen, an analyst with China Fortune Securities said.</p>\n<p>Shares in China's leading battery maker CATL hit an all-time high before closing 3% higher after the company extended a battery supply deal with Tesla Inc to 2025.</p>\n<p>According to Refinitiv data, investors via the Stock Connect linking mainland and Hong Kong sold net 1.3 billion yuan&nbsp;($201.31 million) worth of A-shares on Tuesday.</p>\n<p>($1 = 6.4578 Chinese yuan)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China stocks end lower as virus cases threaten global recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina stocks end lower as virus cases threaten global recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-29 15:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANGHAI, June 29 (Reuters) - China stocks fell on Tuesday on concerns the infectious Delta virus variant could assuage global economic recovery, while investors refrained from placing big bets ahead of U.S. jobs data, which could sway the Federal Reserve's policy outlook.</p>\n<p>The blue-chip CSI300 index closed 1.2% lower at 5,190.54, snapping a five-day winning streak, while the Shanghai Composite Index shed 0.9% to 3,573.18.</p>\n<p>Markets are on edge after the Fed shocked traders with a hawkish tilt earlier this month, while investors adopted a wait-and-watch mode ahead of the U.S. June employment report.</p>\n<p>The retreat from riskier assets followed reports of more contagious Delta COVID-19 strain spread in Asia and elsewhere, stoking fears of further lockdowns.</p>\n<p>The CSI300 financials index declined 1.3%, while the CSI300 consumer staples index dropped 1.8%.</p>\n<p>China will make its monetary policy flexible, targeted and appropriate, while keeping interbank liquidity reasonable, the central bank said on Monday, as authorities seek to consolidate a post-COVID-19 economic recovery.</p>\n<p>The country's economy has seen a rebound from the impact of the COVID-19 pandemic, with Chinese exporters racing ahead to fill global demand bolstering the vast industry sector, but the recovery in the consumer end has been weak.</p>\n<p>\"The net injection by the PBOC was to smoothen liquidity across quarters and the PBOC would probably go back to drain short-term liquidity, while large inflows via the Stock Connect are unsustainable against a backdrop of a stronger dollar,\" Yan Kaiwen, an analyst with China Fortune Securities said.</p>\n<p>Shares in China's leading battery maker CATL hit an all-time high before closing 3% higher after the company extended a battery supply deal with Tesla Inc to 2025.</p>\n<p>According to Refinitiv data, investors via the Stock Connect linking mainland and Hong Kong sold net 1.3 billion yuan&nbsp;($201.31 million) worth of A-shares on Tuesday.</p>\n<p>($1 = 6.4578 Chinese yuan)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"399001":"深证成指","399006":"创业板指","000001.SH":"上证指数"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147854949","content_text":"SHANGHAI, June 29 (Reuters) - China stocks fell on Tuesday on concerns the infectious Delta virus variant could assuage global economic recovery, while investors refrained from placing big bets ahead of U.S. jobs data, which could sway the Federal Reserve's policy outlook.\nThe blue-chip CSI300 index closed 1.2% lower at 5,190.54, snapping a five-day winning streak, while the Shanghai Composite Index shed 0.9% to 3,573.18.\nMarkets are on edge after the Fed shocked traders with a hawkish tilt earlier this month, while investors adopted a wait-and-watch mode ahead of the U.S. June employment report.\nThe retreat from riskier assets followed reports of more contagious Delta COVID-19 strain spread in Asia and elsewhere, stoking fears of further lockdowns.\nThe CSI300 financials index declined 1.3%, while the CSI300 consumer staples index dropped 1.8%.\nChina will make its monetary policy flexible, targeted and appropriate, while keeping interbank liquidity reasonable, the central bank said on Monday, as authorities seek to consolidate a post-COVID-19 economic recovery.\nThe country's economy has seen a rebound from the impact of the COVID-19 pandemic, with Chinese exporters racing ahead to fill global demand bolstering the vast industry sector, but the recovery in the consumer end has been weak.\n\"The net injection by the PBOC was to smoothen liquidity across quarters and the PBOC would probably go back to drain short-term liquidity, while large inflows via the Stock Connect are unsustainable against a backdrop of a stronger dollar,\" Yan Kaiwen, an analyst with China Fortune Securities said.\nShares in China's leading battery maker CATL hit an all-time high before closing 3% higher after the company extended a battery supply deal with Tesla Inc to 2025.\nAccording to Refinitiv data, investors via the Stock Connect linking mainland and Hong Kong sold net 1.3 billion yuan ($201.31 million) worth of A-shares on Tuesday.\n($1 = 6.4578 Chinese yuan)","news_type":1},"isVote":1,"tweetType":1,"viewCount":71,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":159846478,"gmtCreate":1624958215794,"gmtModify":1703848825754,"author":{"id":"3583141439554126","authorId":"3583141439554126","authorIdStr":"3583141439554126","name":"HMLEE","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583141439554126"},"themes":[],"htmlText":"Good one","listText":"Good one","text":"Good one","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/159846478","repostId":"2147832042","repostType":4,"isVote":1,"tweetType":1,"viewCount":310,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153847416,"gmtCreate":1625019220735,"gmtModify":1703850246815,"author":{"id":"3583141439554126","authorId":"3583141439554126","authorIdStr":"3583141439554126","name":"HMLEE","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583141439554126"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153847416","repostId":"1124855646","repostType":4,"repost":{"id":"1124855646","pubTimestamp":1625018860,"share":"https://ttm.financial/m/news/1124855646?lang=&edition=fundamental","pubTime":"2021-06-30 10:07","market":"us","language":"en","title":"China Cancer Drugmaker Surges 28% in Hong Kong Trading Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1124855646","media":"Bloomberg","summary":"Hutchmed (China) Ltd., a cancer drug developer backed by billionaire Li Ka-shing, jumped in its firs","content":"<p>Hutchmed (China) Ltd., a cancer drug developer backed by billionaire Li Ka-shing, jumped in its first day of trade in Hong Kong about two years after it delayed a previous attempt to list in the city.</p>\n<p>Shares of the biopharmaceutical company that already trades in the U.S. and the U.K. opened at HK$51.40 on Wednesday, up 28% from their offer price of HK$40.10. Hutchmedraised$537 million in the offering. It had initially planned a listing in Hong Kong in 2019, but the plan wasshelvedamid market uncertainties at the time.</p>\n<p>Hutchmed’s debut comes after a stellar first half of the year for first-time share sales in the Asian financial hub, with a record $28 billion raised, data compiled by Bloomberg show.</p>\n<p>Prior to Wednesday, almost 59% of the 44 companies that started trading in Hong Kong this year ended their first session higher than the listing price, with eight of them popping more than 50% on their debuts, data compiled by Bloomberg show.</p>\n<p>Shares of property management firmYuexiu Services Group Ltd. ended their first day of trading on Monday flat from their IPO price of HK$4.88. That contrasts with a 259% jump forMorimatsu International Holdings, a Chinese pressure equipment manufacturer which debuted the same day. Earlier this month, China Youran Dairy Group slumped 12% after its $643 millionIPO.</p>\n<p>Chinese bubble tea chain Nayuki Holdings Ltd. fell 5% on its Hong Kong debut on Wednesday.</p>\n<p>Hutchmed’s stock inNew Yorkis up 3.8% this year, while the London-listed shareshave risen 3.3%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Cancer Drugmaker Surges 28% in Hong Kong Trading Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Cancer Drugmaker Surges 28% in Hong Kong Trading Debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 10:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-30/china-cancer-drugmaker-surges-28-in-hong-kong-trading-debut><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hutchmed (China) Ltd., a cancer drug developer backed by billionaire Li Ka-shing, jumped in its first day of trade in Hong Kong about two years after it delayed a previous attempt to list in the city....</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-30/china-cancer-drugmaker-surges-28-in-hong-kong-trading-debut\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HCM":"和黄医药","00013":"和黄医药"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-30/china-cancer-drugmaker-surges-28-in-hong-kong-trading-debut","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124855646","content_text":"Hutchmed (China) Ltd., a cancer drug developer backed by billionaire Li Ka-shing, jumped in its first day of trade in Hong Kong about two years after it delayed a previous attempt to list in the city.\nShares of the biopharmaceutical company that already trades in the U.S. and the U.K. opened at HK$51.40 on Wednesday, up 28% from their offer price of HK$40.10. Hutchmedraised$537 million in the offering. It had initially planned a listing in Hong Kong in 2019, but the plan wasshelvedamid market uncertainties at the time.\nHutchmed’s debut comes after a stellar first half of the year for first-time share sales in the Asian financial hub, with a record $28 billion raised, data compiled by Bloomberg show.\nPrior to Wednesday, almost 59% of the 44 companies that started trading in Hong Kong this year ended their first session higher than the listing price, with eight of them popping more than 50% on their debuts, data compiled by Bloomberg show.\nShares of property management firmYuexiu Services Group Ltd. ended their first day of trading on Monday flat from their IPO price of HK$4.88. That contrasts with a 259% jump forMorimatsu International Holdings, a Chinese pressure equipment manufacturer which debuted the same day. Earlier this month, China Youran Dairy Group slumped 12% after its $643 millionIPO.\nChinese bubble tea chain Nayuki Holdings Ltd. fell 5% on its Hong Kong debut on Wednesday.\nHutchmed’s stock inNew Yorkis up 3.8% this year, while the London-listed shareshave risen 3.3%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159848418,"gmtCreate":1624958173034,"gmtModify":1703848824132,"author":{"id":"3583141439554126","authorId":"3583141439554126","authorIdStr":"3583141439554126","name":"HMLEE","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583141439554126"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/I07.SI\">$ISDN HOLDINGS LIMITED(I07.SI)$</a> Huat ar","listText":"<a href=\"https://laohu8.com/S/I07.SI\">$ISDN HOLDINGS LIMITED(I07.SI)$</a> Huat ar","text":"$ISDN HOLDINGS LIMITED(I07.SI)$ Huat ar","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159848418","isVote":1,"tweetType":1,"viewCount":224,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159849879,"gmtCreate":1624957978891,"gmtModify":1703848822518,"author":{"id":"3583141439554126","authorId":"3583141439554126","authorIdStr":"3583141439554126","name":"HMLEE","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583141439554126"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159849879","repostId":"2147854949","repostType":4,"isVote":1,"tweetType":1,"viewCount":71,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}